Treatment of Nonmetastatic Castration Resistant Prostate Cancer

被引：1
|
作者：
Luo, Jia [1 ]
Beer, Tomasz M. [2 ]
Graff, Julie N. [2 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] VA Portland Hlth Care Syst, Portland, OR USA
来源：
ONCOLOGY-NEW YORK | 2016年 / 30卷 / 04期
关键词：
METASTASIS-FREE SURVIVAL; ANDROGEN-RECEPTOR GENE; ANTIANDROGEN WITHDRAWAL; PHASE-III; MEN; THERAPY; HORMONE; ENZALUTAMIDE; BICALUTAMIDE; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.
引用
收藏
页码：336 / 344
页数：9
相关论文
共 50 条
  • [21] Salvage Radical Prostatectomy in Nonmetastatic Castration-Resistant Prostate Cancer
    Lopez-Fontana, Gaston
    Manuel Guglielmi, Juan
    Lopez-Fontana, Rodrigo
    Lis Hinojosa-Jury, Mariana
    Lopez-Fontana, Constanza
    Daniel Lopez-Laur, Jose
    ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (07): : 638 - 641
  • [22] Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer
    Mori, Keiichiro
    Egawa, Shin
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2021, 79 (03) : 430 - 431
  • [23] Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States
    Swami, Umang
    Hong, Agnes
    Diessner, Brandon
    Young, Christopher
    Bunner, Scott H.
    Xie, Bin
    Ramaswamy, Krishnan
    Chastek, Benjamin
    El Chaar, Nader
    Gupta, Sumati
    FUTURE ONCOLOGY, 2024, 20 (32) : 2467 - 2480
  • [24] FDA Approves Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 498 - 498
  • [25] Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
    Figueiredo, Arnaldo
    Costa, Luis
    Mauricio, Maria Joaquina
    Figueira, Luis
    Ramos, Rodrigo
    Martins-da-Silva, Carlos
    CLINICAL DRUG INVESTIGATION, 2022, 42 (08) : 631 - 642
  • [26] Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
    Arnaldo Figueiredo
    Luís Costa
    Maria Joaquina Maurício
    Luís Figueira
    Rodrigo Ramos
    Carlos Martins-da-Silva
    Clinical Drug Investigation, 2023, 43 : 153 - 154
  • [27] Apalutamide Approved for Use in Nonmetastatic Castration-Resistant Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 273 - 273
  • [28] Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
    Arnaldo Figueiredo
    Luís Costa
    Maria Joaquina Maurício
    Luís Figueira
    Rodrigo Ramos
    Carlos Martins-da-Silva
    Clinical Drug Investigation, 2022, 42 : 631 - 642
  • [29] Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
    Arnaldo Figueiredo
    Luís Costa
    Maria Joaquina Maurício
    Luís Figueira
    Rodrigo Ramos
    Carlos Martins-da-Silva
    Clinical Drug Investigation, 2022, 42 : 1019 - 1020
  • [30] Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer
    Mason, Malcolm
    EUROPEAN UROLOGY, 2018, 74 (06) : 845 - 845
12345